search icon
  • Print
  • ShareThis
  • Text Size

IDSA News Releases

09/19/2014

IDSA applauds White House action and House Committee’s leadership on antibiotic resistance; calls for renewed effort on multi-pronged approach

IDSA President, Dr. Barbara Murray testifies before the House Energy & Commerce Committee on the urgency of fighting Antimicrobial Resistance.
09/18/2014

Antiretroviral Therapies are Beneficial for HIV Patients with Kidney Problems

Antiretroviral therapy (ART) is beneficial for the 5 to 10 percent of HIV-infected patients with reduced kidney function, although tenofovir – the most widely prescribed medication – should be avoided.
09/08/2014

IDSA, HIVMA Call for State Medicaid Programs to Lift Hepatitis C Prescribing Restrictions from ID and HIV Doctors

IDSA and HIVMA urge the Centers for Medicare and Medicaid Services (CMS) to carefully review all state restrictions on the new HCV treatment to ensure they are evidenced-based and to bar states from excluding ID and HIV physicians from prescribing the new HCV treatments.    
08/11/2014

HCV Treatment Recommendations Now Includes Information on Prioritizing Patients Under Limited Resources

AASLD and IDSA released the latest section of their website: “When and in Whom to Initiate HCV Therapy.”
07/22/2014

IDSA Statement on Hepatitis C Antivirals

IDSA is encouraged by the recent development of direct-acting antivirals for the treatment of HCV. We are, however, concerned that pricing of new drugs may put such therapy out of reach for many patients who are most in need of these life-saving drugs.
07/11/2014

Statement from IDSA President Barbara Murray, MD, FIDSA, on PCAST Meeting

IDSA welcomes today’s news about the upcoming report on Antimicrobial Resistance from the President’s Council of Advisors on Science and Technology.
06/19/2014

Increase in MRSA Prompts Updated IDSA Guidelines for Skin and Soft Tissue Infections (SSTI)

IDSA releases updated skin and soft tissue (SSTI) guideline to help physicians diagnose, establish source, cause, and severity, and properly treat SSTIs.
04/24/2014

Feasibility Study Suggests Ways to Widen Access to Fecal Transplants for C. diff Infections

Using frozen stool from unrelated donors for fecal microbiota transplantation (FMT) was effective in a new pilot study in Clinical Infectious Diseases.
03/25/2014

IDSA, Pew Support Regulatory Pathway for Antibiotic Development

IDSA and The Pew Charitable Trusts hailed increasing bipartisan support in Congress for the Antibiotic Development to Advance Treatment Act (ADAPT).
03/07/2014

IDSA Applauds President’s Commitment to Combatting Antibiotic Resistance in FY 2015 Budget, Dismayed by Related Reductions

IDSA Applauds President’s Commitment to Combatting Antibiotic Resistance in FY 2015 Budget, Dismayed by Related Reductions 2014-03-07 /2014_Budget_AR_Initiative/ March 7, 2014 IDSA Applauds President’s Commitment to Combatting Antibiotic Resistance in FY 2015 Budget, Dismayed by Related Reductions The Infe
03/05/2014

President’s Budget Would Double Funds for Antibiotic Resistance

President Obama’s Fiscal Year 2015 budget includes a request to more than double funding for the CDC to combat antibiotic resistance, in addition to requests to fund efforts to track the development of antibiotic resistance in the U.S. and an initiative to detect, prevent and control antimicrobial resistance around the world.
01/31/2014

IDSA Applauds President Obama, Calls for Action on State of the Union Pledge to Address Drug Resistance

The Society praised the President for acknowledging the need for innovation to address drug-resistant bacteria, and urged him to work with Congress to pass the Antibiotic Development to Advance Patient Treatment Act and the Strategies to Address Antimicrobial Resistance Act.
01/30/2014

Online Expert Advice for Clinicians Treating Hepatitis C Now Available at HCVguidelines.org

Online Expert Advice for Clinicians Treating Hepatitis C Now Available at HCVguidelines.org 2014-01-30 /2014_HCVguidelines/ Today, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Societ
//

IDSA President, Dr. Barbara Murray testifies before the House Energy & Commerce Committee on the urgency of fighting Antimicrobial Resistance.
//

IDSA welcomes today’s news about the upcoming report on Antimicrobial Resistance from the President’s Council of Advisors on Science and Technology.
//

IDSA is encouraged by the recent development of direct-acting antivirals for the treatment of HCV. We are, however, concerned that pricing of new drugs may put such therapy out of reach for many patients who are most in need of these life-saving drugs.
//

  IDSA and HIVMA urge the Centers for Medicare and Medicaid Services (CMS) to carefully review all state restrictions on the new HCV treatment to ensure they are evidenced-based and to bar states from excluding ID and HIV physicians from prescribing the new HCV treatments.    
//

Antiretroviral therapy (ART) is beneficial for the 5 to 10 percent of HIV-infected patients with reduced kidney function, although tenofovir – the most widely prescribed medication – should be avoided.
//

Fast Facts: Invasive aspergillosis is a cause of fungal pneumonia that is difficult to diagnose, and it is a leading cause of mortality in immune-compromised patients. Researchers were able to detect key compounds, or metabolites, produced by Aspergillus fungi in the breath of patients with fungal pneumonia. Using this approach, researchers correctly distinguished patients with invasive aspergillosis from those who did not have the illness.

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site